Introduction {#S0001}
============

Respiratory failure due to endobronchial infection is the most important cause of morbidity and mortality in patients suffered from cystic fibrosis (CF) \[[@CIT0001]--[@CIT0003]\]. Bacterial colonization and chronic pulmonary inflammation develop subsequently. It seems that the severity of lung disease could depend on the type of mutation in the cystic fibrosis transmembrane conductance regulator gene (CFTR) \[[@CIT0001]--[@CIT0004]\]. However, there is wide variability in course of the disease, even among patients presenting the same mutation. The genotype-phenotype dependence is still unclear and the course of cystic fibrosis very individual \[[@CIT0005], [@CIT0006]\]. This fact reflects the influence of multiple factors such as genetic, environmental, immunological, time of diagnosis, bacterial colonization and methods of treatment on the disease. Our research with data showing risk factors for lung function deterioration in Polish population can contribute to direct intervention for the relevant patients.

We hypothesized that there are identifiable risk factors in children associated with accelerated lung function aggravation. The aim of the study was to identify risk factors that determine lung disease deterioration in Polish CF children.

Material and methods {#S0002}
====================

We collected information on all living children born between 1996 and 2009 (before the start of newborn screening in Poland) attending the Cystic Fibrosis Outpatient in Copernicus Hospital in Lodz, Poland. The data were obtained retrospectively after review of patient charts. Each patient was observed from the diagnosis until the age of 18; the average time period was 8 years. The data were analyzed in July 2013. The diagnosis of CF was confirmed by clinical symptoms and elevated sweat chloride concentrations (above 60 mmol/l) measured by the quantitative pilocarpine iontophoresis method. The CFTR mutations were analyzed by established DNA molecular techniques. Four patients had one unknown mutation, and the rest had a fixed mutation in both alleles.

The socio-economic data were analyzed. These included number of siblings and siblings with CF, a place of living (defined as big city above 100 000 inhabitants, small city 10 000--100 000 inhabitants and village below 10 000 inhabitants). The perinatal interview contained data: delivery date and weight, Apgar score and presence of meconium ileus (MI). Time of CF diagnosis and start of CF standard therapy (supplementation with pancreatic enzymes, dornase α inhalation, tobramycin inhalation solution (TIS), chronic oral azithromycin intake) were also analyzed. Patients were classified as pancreatic sufficient (PS) or insufficient (PI) by low fecal elastase concentration (\< 200 µg elastase/g). Sensitization to *Aspergillus fumigatus* (allergic bronchopulmonary aspergillosis -- ABPA) was defined as a positive level of serum specific IgE and serum specific IgG antibodies to *Aspergillus* and presence of associated clinical findings. The concomitant diseases were assessed: asthma was established by a personal history and a family history of atopy and asthma in first degree relatives and by the presence of bronchial obstruction, bronchial reactivity \[[@CIT0007]\]; impaired glucose tolerance (IGT)/diabetes mellitus (DM) by the oral glucose tolerance test (OGTT) (2-hour OGTT blood plasma glucose between 7.8 mmol/l (140 mg/dl) and 11.1 mmol/l (200 mg/dl) -- IGT; above 7.8 mmol/l (140 mg/dl) -- DM); nasal polyps by laryngological examination; abdomen abnormalities by ultrasonography, viral hepatitis by presence of the hepatitis B surface antigen (HBsAg) and level of antibodies against hepatitis C virus (anti-HCV). Chronic bacteria colonization (*Pseudomonas aeruginosa* (PA), methicillin-sensitive *Staphylococcus aureus* (MSSA) or methicillin-resistant *Staphylococcus aureus* (MRSA), *Klebsiella* sp., *Haemophilus influenza*, *Serratia marcescens*) was defined as three positive consecutive sputum cultures over a period of 6 months. Respiratory status was assessed by the test of forced expiratory volume in 1 s (FEV~1~) in spirometry, expressed as percentages of predicted values for height, weight, age, and gender. All analyzed measurements were done in the same month, once a year, only in stable periods (with a Jaeger MasterScreen Body spirometer; E Jaeger GmbH; Wurzburg, Germany). The tests were performed according to American Thoracic Society standards \[[@CIT0008]\]. A substantial decline was defined as a decrease of 20 or more percent in FEV~1~% predicted value during at least 5 years of observation. The evaluation of number of bronchopulmonary exacerbations and number of hospitalizations (due to pulmonary or abdominal disease, longer than 3 days) each year of observation was performed. Pulmonary exacerbation was defined as excessive sputum expectoration, general malaise, and need for antibiotics.

The study was approved by the Ethical Committee of the Medical University of Lodz, Poland.

Statistical analysis {#S20003}
--------------------

Here we defined possible risk factors (independent variables) of decline in FEV~1~ among CF children during 5 years of observation (dependent variables). Logistic regression was used to assess the relationship between dependent variables and each of the independent variables. All of the statistical analyses were performed using Statistica 8.0. The null hypothesis was rejected if *p* \< 0.05.

Results {#S0004}
=======

There were 61 patients registered in the Cystic Fibrosis Outpatient Clinic in Copernicus Hospital in Lodz, Poland. The mean age of the group was 13.3 ±7.6 years, and 50.8% were male. Patient demographic and clinical characteristics are shown in [Table I](#T0001){ref-type="table"}. Most of our children were delta F508 homozygous (45.9%), 44.3% were delta F508 heterozygous, and 9.8% had other genotypes. Mean time of the CF diagnosis was 24 months from birth.

###### 

Baseline characteristics

  Variables                                                           Result
  ------------------------------------------------------------------- ---------------
  Age, mean ± SD \[years\]                                            13.3 ±7.6
  Male gender, *n* (%)                                                31 (50.8)
  Birth weight, mean ± SD \[g\]                                       3259 ±522
  APGAR, median (quartile range) \[points\]                           9 (8--9)
  Number of siblings, median (quartile range)                         1 (0--1)
  Siblings with CF, *n* (%)                                           14 (23.3)
  Meconium ileus, *n* (%)                                             15 (24.6)
  Place of living, *n* (%):                                           
   Village                                                            12 (19.7)
   Small city                                                         31 (50.8)
   Big city                                                           18 (29.5)
  Time of diagnosis, median (quartile range) \[months\]               24 (3--69)
  Sweat chloride concentrations \[mmol/l\], median (quartile range)   100 (90--113)
  Mutation (CFTR), *n* (%):                                           
   Delta F508/other                                                   27 (44.3)
   Delta F508/Delta F508                                              28 (45.9)
   Others                                                             6 (9.8)
  Impaired glucose tolerance, *n* (%)                                 14 (23.3)
  Pancreatic insufficiency, *n* (%)                                   53 (98.1)

All continues variables with skewed distribution were log-transformed before analysis. The most significant predictors related to the decline of FEV~1~ ([Table II](#T0002){ref-type="table"}) were presentation of MI in newborn and number of exacerbations. Impaired glucose tolerance was a risk factor in CF children older than 10 years of age. Patients with early PA chronic colonization and late TIS introduction (after first detection of PA) showed faster decline of FEV~1~. Neither time of diagnosis nor type of CFTR mutation was statistically significant as a predictor of lung deterioration. Other demographic, clinical and health care utilization characteristics described in [Table II](#T0002){ref-type="table"} were not predictors of substantial decline. In the analysis cohort, FEV~1~ decline was observed among 20% of patients; the remaining 80% of patients presented quite stable values of FEV~1~ during at least 5 years of observation ([Figure 1](#F0001){ref-type="fig"}).

![Lung function decline among 20% of CF patients (■) and stable values of FEV1 among 80% of CF patients (●) during five years of observation](AMS-12-27372-g001){#F0001}

###### 

Risk factors of decline in FEV~1~ in univariate model of logistic regression analysis

  Coefficient                                OR[a](#TF0001){ref-type="table-fn"}   Lower 95% CI   Upper 95% CI   *P*-value
  ------------------------------------------ ------------------------------------- -------------- -------------- ------------
  Age (continuous variable)                  1.07                                  0.96           1.19           0.2435
  Time of diagnosis \[months\]               1.01                                  0.99           1.02           0.4315
  Gender                                     0.86                                  0.21           3.44           0.8280
  Weight                                     1.00                                  1.00           1.00           0.1755
  Apgar score                                1.50                                  0.64           3.56           0.3527
  Meconium ileus                             5.83                                  1.14           29.90          **0.0344**
  Place of living                            Ref                                                                 
  Small city                                 1.00                                  0.16           6.25           1.0000
  Big city                                   1.09                                  0.15           8.12           0.9323
  Siblings                                   1.03                                  0.46           2.32           0.9392
  Siblings with CF                           0.64                                  0.12           3.48           0.6021
  CFTR mutation                              1.75                                  0.43           7.19           0.4377
  Sweat chloride concentration               1.00                                  0.97           1.04           0.9280
  Impaired glucose tolerance                 5.62                                  1.27           24.86          **0.0227**
  ABPA                                       1.21                                  0.79           1.83           0.3814
  First exacerbation in life                 1.03                                  0.99           1.07           0.1615
  First hospitalization in life              1.01                                  0.98           1.05           0.3668
  Exacerbations (all)                        1.09                                  1.01           1.17           **0.0288**
  Hospitalizations (all)                     1.10                                  0.99           1.22           0.0872
  Start of nebulised dornase α               1.00                                  0.98           1.01           0.6638
  Start of tobramycin inhalation solution    1.02                                  1.00           1.03           **0.0071**
  Start of chronic oral azithromycin         1.00                                  0.99           1.02           0.3854
  First *Pseudomonas aeruginosa* infection   1.00                                  0.99           1.01           0.5039
  Chronic *Pseudomonas aeruginosa*           1.01                                  1.00           1.02           **0.0165**
  Chronic MRSA infection                     1.01                                  1.00           1.02           0.1690
  Chronic MSSA infection                     1.00                                  0.99           1.01           0.9718
  First *Hemophilus influenzae* infection    0.99                                  0.97           1.01           0.4507
  First *Klebsiella* sp. infection           1.01                                  1.00           1.02           0.1235
  First *Serratia* sp. infection             1.01                                  0.99           1.02           0.4257

Dependent variable: decline in FEV~1~.

Discussion {#S0005}
==========

Although this type of analysis has been published in numerous other settings among CF populations in North America and Western Europe, a similar analysis in this population is useful to show differences in health systems and access to therapies. Our research team has collected large amount of data over many years, and the concept of what factors determine lung function decline in some CF children is an important one for clinicians and researchers. We observed wide variability in disease severity even among children with the same CFTR mutation. Pulmonary function is the best predictor of morbidity in patients with cystic fibrosis and is the most widely used clinical end point in therapeutic trials and to describe and compare groups in a regression model \[[@CIT0009], [@CIT0010]\]. In our study, the analyzed data present two patterns of changes in lung function in time: a continuous decline in values of FEV~1~, and a second pattern that showed lung function at quite a stable level over time despite genotype and related medical interventions in accordance with the guidelines. We observed that children with an important decline in FEV~1~ started the observation period with an initial lower FEV~1~. This is consistent with the previous finding that patients with lower FEV~1~ were at further risk of a substantial decline \[[@CIT0011]\]. At high risk of unfavorable presentation of the disease was the group of children with MI in newborn and IGT at the age of 10 years. Earlier acquisition of chronic *Pseudomonas aeruginosa* colonization was associated with faster deterioration of lung function. The administration of inhaled antibiotics, especially inhaled tobramycin, had a beneficial effect on the general condition of CF patients with PA colonization. Moreover, patients who started treatment with TIS earlier had slower decline of FEV~1~. Interestingly, the time of diagnosis of CF was not prognostic for the severity of the disease, even if patients presented severe mutation in both alleles of CFTR. This highlights the fact that the CFTR genotype known at the time of CF diagnosis is not representative for estimating phenotype of the disease in the future.

Meconium ileus is a unique manifestation among infants with CF and is the earliest clinical symptom, with the prevalence of 10--21% \[[@CIT0012], [@CIT0013]\]. Despite the fact that children presenting MI are diagnosed and adequate treatment is initiated soon after birth, many researchers have noted in these patients poor growth, nutritional status and worse lung function \[[@CIT0012]--[@CIT0015]\]. Additionally, publications by the Wisconsin CF Neonatal Screening Project showed that MI children with CF present a specific phenotype, predisposing to malnutrition, severe pulmonary deterioration, and reduced survival \[[@CIT0015]--[@CIT0017]\]. Likewise, in the present study, a worse course of the disease was observed particularly among children who were treated surgically due to MI, and who experienced more exacerbations and admission to the hospital per year. They presented more impaired growth and severe malnutrition status in comparison to patients without MI. However, there are also suggestions that if the follow-up period was extended to 20 years of age, the influence of MI on the morbidity diminished \[[@CIT0018]\].

Most studies report rapid decline of lung function in diabetic CF patients \[[@CIT0019], [@CIT0020]\]. Nowadays, the significance of IGT as a risk factor of worse clinical condition, undernutrition and impaired pulmonary function is also increasingly emphasized \[[@CIT0006], [@CIT0021]--[@CIT0023]\]. A similar observation was noted in our study. We found that glucose abnormalities are related to the faster decline of FEV~1~. These findings open the question whether early treatment of mild alterations of glucose metabolism with short-acting insulin may lead to improvement of clinical status in CF patients. Moran *et al*. \[[@CIT0021]\] reported that insulin therapy in children with IGT improved lung function and restored body mass index (BMI). In the study by Lanng *et al*. \[[@CIT0022]\] weight loss and decrease of lung function were observed in CF patients 1--4 years before DM diagnosis. Early treatment with short-acting insulin in CF patients with IGT without fasting hyperglycemia is still not generally recommended. There is a need for further investigation and changes in the guidelines.

Colonization with *Pseudomonas aeruginosa* remains the major contributor to the shortened survival in CF patients. For over a decade tobramycin inhalation solution (TIS) has been recommended for the treatment of PA infection in CF. Our results showed that early initiation of TIS treatment resulted in improved lung function and reduced the risk of airway exacerbations, which was confirmed in other studies \[[@CIT0024]--[@CIT0026]\]. What is very important, Moss *et al*. \[[@CIT0026]\] proved that delay in initiation of TIS therapy is associated with reduced long-term improvement over baseline, suggesting an irreversible component to lung function decline. They also demonstrated that long-term, intermittent TIS therapy may lead to significant improvement of body weight in growing adolescents. They also strongly suggested that in order to be maximally effective, TIS treatment should begin soon after first detection of PA. In accordance with that study, we found a slower decline in FEV~1~ among children whose TIS was administered shortly after chronic infection of PA. Unfortunately, in Poland TIS is only available for patients with chronic PA (positive sputum culture over 6 months).

This study has some limitations. Only patients who had at least five visits in the 5 years before the data collection were included in the analysis cohort. This allowed more rigorous assessment, but reduced the available cohort.

In our study, multivariable analysis would be of interest; however, all statistical predictors of FEV~1~ decline defined in our study seem to have different pathophysiological meaning, and collinearity is less possible.

In conclusion, our study revealed that presence of meconium ileus, impaired glucose tolerance, chronic *Pseudomonas* colonization, and number of exacerbations are risk factors for lung function deterioration. Patients with these characteristics should receive early and aggressive treatment. Despite genotype and treatment, 80% of our patients had stable lung function in time, which is probably associated with other genetic factors.
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